Long-acting injections for HIV prevention among women in sub-Saharan Africa

Affiliations

¹ Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT 06269-1248, USA. Electronic address: emily.krogstad@uconn.edu.
² J Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.

Comment

Emily Krogstad Mudzingwa et al. Lancet. 2022.

. 2022 May 7;399(10337):1754-1755.

doi: 10.1016/S0140-6736(22)00613-4. Epub 2022 Apr 1.

¹ Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT 06269-1248, USA. Electronic address: emily.krogstad@uconn.edu.
² J Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.

No abstract available

Comment on

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Delany-Moretlwe S, et al. Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Lancet. 2022. PMID: 35378077 Free PMC article. Clinical Trial.